Reconceptualising treatment-resistant depression as difficult-to-treat depression

TY - JOUR

T1 - Reconceptualising treatment-resistant depression as difficult-to-treat depression

AU - McAllister-Williams, R Hamish

AU - Arango, Celso

AU - Blier, Pierre

AU - Demyttenaere, Koen

AU - Falkai, Peter

AU - Gorwood, Philip

AU - Hopwood, Malcolm

AU - Javed, Afzal

AU - Kasper, Siegfried

AU - Malhi, Gurjhinder S

AU - Soares, Jair C

AU - Vieta, Eduard

AU - Young, Allan H

AU - Papadopoulos, Andreas

AU - Rush, Augustus J

N1 - Funding Information: RHM-W has received fees from American Center for Psychiatry & Neurology United Arab Emirates, AstraZeneca, British Association for Psychopharmacology, European College of Neuropsychopharmacology, International Society for Affective Disorders, Janssen, LivaNova, Lundbeck, My Tomorrows, OCM Comunicaziona, P1Vital, Pfizer, Qatar International Mental Health Conference, Sage Therapeutics, Sunovion, Syntropharma, UK Medical Research Council, and Wiley; grant support from National Institute for Health Research Efficacy and Mechanism Evaluation Panel and Health Technology Assessment Panel; and non-financial support from COMPASS Pathways and Magstim, outside the submitted work. CA has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, LivaNova, Lundbeck, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion, and Takeda, outside the submitted work. KD has been involved in advisory boards and speaker bureaus with Boehringer Ingelheim, Johnson & Johnson, LivaNova, Lundbeck, and Servier, outside the submitted work. PB has received honoraria for participation in advisory boards, giving lectures, or providing expert testimony for Allergan, Bristol Myers Squibb, Janssen, LivaNova, Lundbeck, Otsuka, Pierre Fabre Médicaments, Pfizer, Sunovion, and Takeda, outside the submitted work. PF has received research support and honoraria for lectures from Abbott, Janssen, Lundbeck, Otsuka, Recordati, Richter, Servier, and Takeda, outside the submitted work. PG has received fees for presentations at congresses or participation in scientific boards from Alcediag-Alcen, AstraZeneca, Bristol Myers Squibb, GSK, Janssen, Lilly, Lundbeck, Otsuka, and Servier, outside the submitted work. MH has received speaker fees or honoraria from Eli Lilly, Janssen-Cilag, Lundbeck, and Servier; has served on advisory boards for the Defence Health Foundation, Eli Lilly, Jansen-Cilag, Lundbeck, Phoenix, RANZCP, and Summer Foundation; has received travel support from Lundbeck and Servier; and has had clinical trials or research support from AHMRF, Bionomics, Douglass, ISSCR, Jansen-Cilag, Lundbeck, Lyndra, MRFF, NHMRC, Praxis, Paul Ramsay Foundation, Servier, and Weary Dunlop Foundation, outside the submitted work. AJ has received fees for presentations at congresses or participation in scientific boards from Lundbeck, Otsuka, and Sunovion, outside the submitted work. SK has received grants or research support, and consulting fees or honoraria from Angelini, AOP Orphan Pharmaceuticals, Celgene, Eli Lilly, Janssen-Cilag, KRKA, Lundbeck, Mundipharma, Neuraxpharm, Pfizer, Sage, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon, and Takeda, outside the submitted work. GSM has received grant or research support from National Health and Medical Research Council, Australian Rotary Health, NSW Health, Ramsay Health, American Foundation for Suicide Prevention, Ramsay Research and Teaching Fund, Elsevier, AstraZeneca, and Servier; has been a speaker for AstraZeneca, Janssen-Cilag, Lundbeck, Otsuka, and Servier; and has been a consultant for AstraZeneca, Janssen Cilag, Lundbeck, Otsuka, and Servier, outside the submitted work. JCS has received research support from COMPASS Pathways, Alkermes, Pfizer, and Allergan; is a consultant for Johnson & Johnson; and has been involved in speaker bureaus for Sunovian and Sanofi, outside the submitted work. EV has received grants and served as a consultant, advisor, or continuing medical education speaker for AB-Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo, Galenica, Janssen, Lundbeck, Novartis, Otsuka, Sage, Sanofi-Aventis, and Takeda, outside the submitted work. AHY is funded by the National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London; receives fees for lectures and advisory boards for AstraZeneca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, and Bionomics; is a consultant to Johnson & Johnson and to LivaNova; has received honoraria for attending advisory boards and presenting talks at meetings organised by LivaNova; is the Principle Investigator in the Restore-Life vagus nerve stimulation registry study funded by LivaNova, Lead Investigator for the Embolden study (AstraZeneca), Brain Cells Neuroplasticity study, and Aripiprazole Mania study, investigator-initiated studies from AstraZeneca, Eli Lilly, Lundbeck, Wyeth, and Janssen; has received grants from National Institute of Mental Health (USA); Canadian Institutes of Health Research; Brain & Behavior Research Foundation (USA); Stanley Medical Research Institute (USA); Medical Research Council (UK); Wellcome Trust; Royal College of Physicians (UK); British Medical Association; UBC-VGH Foundation (Canada); Western Economic Diversification Canada; CCS Depression Research Fund (Canada); Michael Smith Foundation For Health Research (Canada); National Institute for Health Research; and Janssen. AP has received fees for presentations at educational events and participation in advisory boards from Janssen, Lundbeck, Otsuka, LivaNova, and Magstim, outside the submitted work. AJR has received consulting fees from Akili Brain Resource, Compass, Curbstone Consultant, Emmes, Johnson & Johnson (Janssen), LivaNova, Mind Linc, and Sunovion; speaking fees from LivaNova; and royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX, USA (for the Inventory of Depressive Symptoms and its derivatives); and is named co-inventor on two patents: US patent number 7 795 033: methods to predict the outcome of treatment with antidepressant medication, and US patent number 7 906 283: methods to identify patients at risk of developing adverse events during treatment with antidepressant medication. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/1/2

Y1 - 2021/1/2

UR - http://www.scopus.com/inward/record.url?scp=85098565039&partnerID=8YFLogxK

U2 - 10.1016/S2215-0366(20)30516-2

DO - 10.1016/S2215-0366(20)30516-2

M3 - Letter

C2 - 33341160

SN - 2215-0366

VL - 8

SP - 14

EP - 15

JO - The lancet. Psychiatry

JF - The lancet. Psychiatry

IS - 1

ER -